MARKET

ICPT

ICPT

Intercept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.26
-0.89
-4.90%
After Hours: 17.26 0 0.00% 16:53 05/17 EDT
OPEN
17.97
PREV CLOSE
18.15
HIGH
18.27
LOW
17.20
VOLUME
581.97K
TURNOVER
--
52 WEEK HIGH
94.51
52 WEEK LOW
16.26
MARKET CAP
572.38M
P/E (TTM)
-2.5630
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 5d ago
Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 12, May 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a...
GlobeNewswire · 5d ago
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 6d ago
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 6d ago
--Oppenheimer Adjusts Intercept Pharmaceuticals PT to $20 From $33 Following Q1 Results and Update, Maintains Perform Rating
MT Newswires · 05/10 11:33
If You Had Bought Intercept Pharmaceuticals' (NASDAQ:ICPT) Shares Five Years Ago You Would Be Down 87%
Simply Wall St. · 05/10 09:58
Intercept Pharma (ICPT) Gets a Hold Rating from Oppenheimer
SmarterAnalyst · 05/10 03:25
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
Zacks.com · 05/07 16:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICPT. Analyze the recent business situations of Intercept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICPT stock price target is 37.05 with a high estimate of 82.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 305
Institutional Holdings: 27.62M
% Owned: 83.29%
Shares Outstanding: 33.16M
TypeInstitutionsShares
Increased
23
1.71M
New
10
180.48K
Decreased
35
2.08M
Sold Out
24
418.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Director
Paolo Fundaro
President/Chief Executive Officer/Chief Operating Officer/Director
Jerome Durso
Chief Financial Officer/Chief Accounting Officer/Controller
Rocco Venezia
Corporate Executive
Lisa Bright
Chief Human Resource Officer
David Ford
Executive Vice President
Christian Weyer
Senior Vice President
Gail Cawkwell
Senior Vice President
Lisa DeFrancesco
Other
Jason Campagna
Other
Linda Richardson
Lead Director/Independent Director
Gino Santini
Independent Director
Srinivas Akkaraju
Independent Director
Luca Benatti
Independent Director
Daniel Bradbury
Independent Director
Keith Gottesdiener
Independent Director
Nancy Miller-Rich
Independent Director
Nancy Miller-rich
Independent Director
Dagmar Rosa-Bjorkeson
Independent Director
Glenn Sblendorio
Independent Director
Daniel Welch
No Data
About ICPT
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Webull offers kinds of Intercept Pharmaceuticals Inc stock information, including NASDAQ:ICPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICPT stock methods without spending real money on the virtual paper trading platform.